Washington, D.C. 20549







PURSUANT TO RULE 13a-16 OR 15d-16


For the Month of July 2019

Commission File Number: 001-38281




(Translation of registrant’s name into English)



60 Avenue Rockefeller

69008 Lyon France

(Address of principal executive office)



Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒  Form 20-F            ☐  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐




New Director Appointment

On June 21, 2019, at the combined general shareholders’ meeting of ERYTECH Pharma S.A. (the “Company”) to approve the financial statements for the year ended December 31, 2018, the Company’s shareholders elected Jean-Paul Kress, M.D. to the board of directors of the Company (the “Board”) for a three-year term that will end at the close of the ordinary general meeting of shareholders to be held in 2022 to approve the financial statements for the year ending December 31, 2021. Subsequently, the Board approved the separation of the roles of Chairman of the Board of Directors and Chief Executive Officer and appointed Dr. Kress to serve as the Chairman of the Board.

Dr. Kress was recently appointed as Chief Executive Officer of MorphoSys AG, a position to take effect on September 1, 2019. He previously served as President and Chief Executive Officer and a member of the Board of Directors of Syntimmune, Inc. from January 2018 until its acquisition by Alexion Pharmaceuticals in November 2018. Prior to joining Syntimmune, Dr. Kress served as the Executive Vice President, President of International and Head of Global Therapeutic Operations at Biogen Inc. Prior to then, Dr. Kress served as Senior Vice President, Head of North America at Sanofi Genzyme. From July 2011 to September 2015, Dr. Kress served as President and Chief Executive Officer of Sanofi Pasteur MSD, a European vaccine company. Prior to then, Dr. Kress held various senior commercial and business development roles of increasing responsibility at Gilead Sciences, Inc., AbbVie and Eli Lilly in the United States and in Europe. He was a member of Sarepta Therapeutics’ board of directors from 2015 until 2017. Dr. Kress holds an M.D. degree from Faculté Necker-Enfants Malades in Paris, and graduate and post-graduate degrees from École Normale Supérieure in Paris.

Press Release

On July 16, 2019, the Company issued a press release regarding (i) Dr. Kress’ election as director and appointment as Chairman and (ii) the voting results of its Annual General Meeting held on June 21, 2019. A copy of the press release is attached to this Form 6-K as Exhibit 99.1.





99.1    Press Release dated July 16, 2019.


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


    ERYTECH Pharma S.A.
Date: July 16, 2019                  By:  

/s/ Eric Soyer

    Name   Eric Soyer
    Title:   Chief Financial Officer and Chief Operating Officer

Exhibit 99.1



ERYTECH Pharma Reports Voting Results from Annual

General Meeting Held on June 21, 2019



Lyon (France) and Cambridge (U.S.), July 16, 2019 – ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP) announced that its 2019 Annual General Meeting was held in Paris on Friday, June 21, 2019.

At the meeting, all resolutions for which management recommended a vote in favor, were adopted, including:



Appointment of Jean-Paul KRESS as director; he was subsequently appointed to the position of Chairman of the Board of Directors;


Renewal of the term of office of each of the following as a member of the Board of Directors:








Galenos, represented by Sven ANDREASSON;


Approval of the annual financial statements and consolidated financial statements for the year ended December 31, 2018 and quietus of directors;


Allocation of the financial year’s results;


Approval of regulatory agreements and commitments referred to in Article L.225-38 of the French Commercial Code;


Approval of the regulations of the share subscription and/or purchase options plan adopted by the Board of Directors on September 7, 2018;


Approval of the elements of the compensation policy for executive corporate officers and approval of the elements of fixed, variable and exceptional compensation allocated to Gil Beyen for the year ended December 31 2018;


“Financial” delegations of authority to the Board of Directors to issue shares or other marketable securities convertible to the shares to be issued immediately or in the future by the Company, with or without the preferential subscription rights of the shareholders; and


Authorization for the Board of Directors to grant free shares, share subscription and/or share purchase options and/or to issue detachable share subscription warrants to corporate officers and employees of the Company or companies in the ERYTECH Pharma Group.

The full results of all matters voted on at the meeting can be viewed on the Company’s website at www.erytech.com, under the Shareholders Meeting tab within the Investors/Shareholders meetings/2019 section.

About ERYTECH: www.erytech.com

ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs.

ERYTECH’s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival. The Company’s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cell’s altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of triple-negative breast cancer. ERYTECH is also developing erymethionase, which consists of methionine-gamma-lyase encapsulated in red blood cells to target methionine-dependent cancers.

ERYTECH produces product candidates at its GMP-approved manufacturing site in Lyon, France, and at the American Red Cross in Philadelphia, USA. A large-scale GMP manufacturing facility has recently opened for operations in Princeton, New Jersey, USA and will begin manufacturing later this year.

ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.






Eric Soyer






Mathilde Bohin / Louis-Victor Delouvrier


Investor relations


Nicolas Merigeau


Media relations




+33 4 78 74 44 38




+33 1 44 71 98 52